Jump to content

User:Mr. Ibrahem/Pomalidomide

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Pomalidomide
Clinical data
Trade namesPomalyst, Imnovid
AHFS/Drugs.comMonograph
MedlinePlusa613030
License data
Pregnancy
category
  • AU: X (High risk)[1]
Routes of
administration		By mouth (capsules)
Drug classThalidomide analog[2]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)[3]
  • US: ℞-only[4]
  • EU: Rx-only[5]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability73% (at least)[6]
Protein binding12–44%
MetabolismLiver (mostly CYP1A2- and CYP3A4-mediated; some minor contributions by CYP2C19 and CYP2D6)
Elimination half-life7.5 hours
ExcretionUrine (73%), faeces (15%)
Identifiers
  • 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Chemical and physical data
FormulaC13H11N3O4
Molar mass273.248 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
  • InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) ☒N
  • Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Pomalidomide, sold under the brand name Pomalyst and Imnovid, is a medication used to treat multiple myeloma (MM) and Kaposi sarcoma (KS).[4] For MM it is used when other treatments have failed.[4] For KS it is used when HAART is not affected or in those who are HIV negative.[4] It is taken by mouth.[4]

Common side effects include tiredness, low neutrophils, low red blood cells, nausea, diarrhea, shortness of breath, fever, and low platelets.[4] Other side effects may include liver problems, tumor lysis syndrome, blood clots, and anaphylaxis.[4] Use in pregnancy may harm the baby.[4] It is similar to thalidomide and works by altering the immune system.[2][5]

Pomalidomide was approved for medical use in the United States and Europe in 2013.[4][5] In the United Kingdom 4 weeks of treatment costs the NHS about £8,900 as of 2021.[7] In the United States this amount costs about 20,000 USD.[8]

References[edit]

  1. ^ "Pomalidomide (Pomalyst) Use During Pregnancy". Drugs.com. 14 May 2020. Archived from the original on 25 January 2021. Retrieved 21 September 2020.
  2. ^ a b c "Pomalidomide Monograph for Professionals". Drugs.com. Archived from the original on 7 September 2015. Retrieved 28 October 2021.
  3. ^ "Imnovid 1 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 16 June 2020. Archived from the original on 26 October 2020. Retrieved 21 September 2020.
  4. ^ a b c d e f g h i j k "Pomalyst- pomalidomide capsule". DailyMed. 7 December 2017. Archived from the original on 20 October 2020. Retrieved 21 September 2020.
  5. ^ a b c "Imnovid EPAR". European Medicines Agency (EMA). Archived from the original on 27 October 2020. Retrieved 21 September 2020.
  6. ^ "Imnovid 1 mg Hard Capsules. Summary of Product Characteristics. 5.2 Pharmacokinetic properties" (PDF). Celgene Europe Ltd. p. 22. Archived (PDF) from the original on 27 June 2016. Retrieved 21 August 2016.
  7. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1004. ISBN 978-0857114105.
  8. ^ "Pomalyst Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 22 August 2021. Retrieved 28 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Pomalidomide&oldid=1211765366"